uniQure (NASDAQ:QURE) Shares Gap Up Following Analyst Upgrade

Shares of uniQure (NASDAQ:QUREGet Rating) gapped up before the market opened on Wednesday after The Goldman Sachs Group raised their price target on the stock from $47.00 to $57.00. The stock had previously closed at $23.00, but opened at $23.79. The Goldman Sachs Group currently has a buy rating on the stock. uniQure shares last traded at $24.25, with a volume of 9,095 shares traded.

Other analysts have also recently issued reports about the stock. Chardan Capital decreased their price target on shares of uniQure from $65.00 to $60.00 and set a “buy” rating for the company in a report on Tuesday, August 9th. Wells Fargo & Company decreased their price target on shares of uniQure from $34.00 to $24.00 and set an “equal weight” rating for the company in a report on Tuesday, August 9th. StockNews.com assumed coverage on shares of uniQure in a report on Wednesday, October 12th. They set a “sell” rating for the company. Truist Financial raised their price target on shares of uniQure from $51.00 to $65.00 in a report on Wednesday. Finally, TheStreet cut shares of uniQure from a “c-” rating to a “d” rating in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.71.

Insider Activity at uniQure

In related news, VP Alexander Edward Kuta III sold 2,306 shares of the firm’s stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $18.65, for a total transaction of $43,006.90. Following the transaction, the vice president now owns 92,890 shares of the company’s stock, valued at $1,732,398.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. bought a new position in shares of uniQure in the first quarter valued at approximately $27,000. Captrust Financial Advisors raised its position in shares of uniQure by 1,392.3% in the second quarter. Captrust Financial Advisors now owns 1,940 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 1,810 shares during the period. US Bancorp DE raised its position in shares of uniQure by 108.2% in the second quarter. US Bancorp DE now owns 1,978 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,028 shares during the period. PNC Financial Services Group Inc. raised its position in shares of uniQure by 152.5% in the first quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,231 shares during the period. Finally, Covestor Ltd bought a new position in shares of uniQure in the first quarter valued at approximately $50,000. Institutional investors own 86.46% of the company’s stock.

uniQure Stock Performance

The company has a market cap of $1.23 billion, a P/E ratio of -9.80 and a beta of 0.96. The company has a quick ratio of 7.20, a current ratio of 7.26 and a debt-to-equity ratio of 0.24. The stock’s 50-day moving average price is $19.61 and its 200 day moving average price is $19.08.

About uniQure

(Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Featured Articles

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.